kt-5000AI delivers potent and selective ATR inhibition, CNS-oriented properties and preclinical tumour-growth control, advancing a capital-efficient drug discovery program toward candidate selection Read More
Source link
CI Global Asset Management Announces Monthly Cash Distributions for October 2026 for Certain CI ETFs
Article content Certain names, words, titles, phrases, logos, icons, graphics, or designs in this document may constitute trade names, registered or unregistered trademarks or service marks of CI Investments Inc.,…




